M. Anderson, H. Naci, D. Morrison, L. Osipenko, and E. Mossialos, A review of NICE appraisals of pharmaceuticals 2000-2016 found variation in establishing comparative clinical effectiveness, J Clin Epidemiol, vol.105, pp.50-59, 2019.

R. F. Spiera, J. K. Gordon, J. N. Mersten, C. M. Magro, M. Mehta et al.,

, mesylate (Gleevec) in the treatment of diffuse cutaneous systemic sclerosis: results of a 1-year, phase

. Iia, single-arm, open-label clinical trial, Ann Rheum Dis, vol.70, issue.6, pp.1003-1012, 2011.

S. Prey, K. Ezzedine, A. Doussau, A. S. Grandoulier, D. Barcat et al., Imatinib mesylate in scleroderma-associated diffuse skin fibrosis: a phase II multicentre randomized doubleblinded controlled trial, Br J Dermatol, vol.167, issue.5, pp.1138-1182, 2012.

D. Khanna, C. P. Denton, A. Jahreis, J. M. Van-laar, T. M. Frech et al., Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial, Lancet, vol.387, pp.2630-2670, 2016.

D. Food and . Administration, Rare diseases: natural history studies for drug development. Guidance for industry, 2019.

J. C. Foster, B. Freidlin, C. A. Kunos, and E. L. Korn, Single-arm phase ii trials of combination therapies: a review of the CTEP experience 2008-2017, J Natl Cancer Inst, p.193, 2019.

P. Group, P. Multi-national, R. T. Davey, J. Dodd, L. Proschan et al., A randomized, controlled trial of ZMapp for Ebola virus infection, N Engl J Med, vol.375, issue.15, pp.1448-56, 2016.

E. L. Korn, P. Y. Liu, S. J. Lee, J. A. Chapman, D. Niedzwiecki et al., Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials, J Clin Oncol, vol.26, issue.4, pp.527-561, 2008.

, Choice of control group and related issues in clinical trials E10. ICH harmonised tripartite guideline: International Conference on Harmonisation of technical requirements for registration of pharmaceuticals for human use, 2000.

D. M. Phillippo, A. E. Ades, S. Dias, S. Palmer, K. R. Abrams et al., Methods for populationadjusted indirect comparisons in health technology appraisal, Med Decis Making, 2018.

, Feb, vol.38, issue.2, pp.200-211

J. E. Signorovitch, V. Sikirica, M. H. Erder, J. Xie, M. Lu et al., Matching-adjusted indirect comparisons: a new tool for timely comparative effectiveness research, Value Health, vol.15, issue.6, pp.940-947, 2012.

J. E. Signorovitch, E. Q. Wu, A. P. Yu, C. M. Gerrits, E. Kantor et al., Comparative effectiveness without head-to-head trials: a method for matching-adjusted indirect comparisons applied to psoriasis treatment with adalimumab or etanercept, Pharmacoeconomics, vol.28, issue.10, pp.935-980, 2010.

J. J. Caro and K. J. Ishak, No head-to-head trial? simulate the missing arms, Pharmacoeconomics, vol.28, issue.10, pp.957-67, 2010.

D. M. Phillippo, S. Dias, S. Palmer, K. R. Abrams, and N. J. Welton, NICE DSU technical support document 18: methods for population-adjusted indirect comparisons in submissions to NICE. NICE DSU technical support document NICE, 2016.

S. Geenland and T. Lash, Bais analysis, Philadelphia: Lippincott Williams and, pp.345-80, 2008.

, clinical trials E10. International Conference on Harmonisation of technical requirements for registration of pharmaceuticals for human use, 2019.

V. Hoff, D. D. Stephenson, J. J. , J. Rosen, P. Loesch et al., Pilot study using molecular profiling of patients' tumors to find potential targets and select treatments for their refractory cancers, J Clin Oncol, vol.28, issue.33, pp.4877-83, 2010.

S. Watson, J. Menis, C. Baldini, P. Martin-romano, J. M. Michot et al., Time to progression ratio in cancer patients enrolled in early phase clinical trials: time for new guidelines?, Br J Cancer, vol.119, issue.8, pp.937-946, 2018.

M. Buyse, E. Quinaux, A. Hendlisz, V. Golfinopoulos, C. Tournigand et al., Progression-free survival ratio as end point for phase II trials in advanced solid tumors, J Clin Oncol, vol.29, issue.15, pp.451-453, 2011.